Rheumatology

Latest News

FDA approves ustekinumab-ttwe as biosimilar for pediatric plaque psoriasis, active psoriatic arthritis | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves ustekinumab-ttwe as biosimilar for pediatric plaque psoriasis, active psoriatic arthritis

July 9th 2024

An intentional launch date for ustekinumab-ttwe in the United States is set for sometime in February 2025.

FDA approves sarilumab to treat active polyarticular juvenile idiopathic arthritis | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves sarilumab to treat active polyarticular juvenile idiopathic arthritis

June 11th 2024

Now available: upadacitinib to treat JIA, psoriatic arthritis in patients 2 years and up | Image Credit: © vectorwin - © vectorwin - stock.adobe.com.
Now available: upadacitinib to treat JIA, psoriatic arthritis in patients 2 years and up

June 4th 2024

Early-onset IBD linked to greater risk of diseases with possible autoimmune pathogenesis | Image Credit: © chrupka - © chrupka - stock.adobe.com.
Early-onset IBD linked to greater risk of diseases with possible autoimmune pathogenesis

March 27th 2024

FDA approves tocilizumab-bavi as biosimilar for PJIA, SJIA in children 2 years and up | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves tocilizumab-bavi as biosimilar for PJIA, SJIA in children 2 years and up

October 2nd 2023

More News

© 2024 MJH Life Sciences

All rights reserved.